Palatin prelim Q1: Vyleesi gross revenue $4.6M, net $2.1M, up 100% and 137% YoY

PALATIN TECHNOLOGIES INC

Gross product revenue $4.6M (+11% qoq, +100% YoY); net product revenue $2.1M (+18% qoq, +137% YoY).
Prescriptions dispensed grew 14% over prior quarter and 88% over comparable quarter last year.
Seventh consecutive quarter of double-digit growth in product revenue and prescriptions dispensed.
CEO reports net revenue per prescription improving; net product revenue exceeds Vyleesi quarterly operating expenses.
All key metrics (new patient starts, refill rates, insurance reimbursement, new prescribers) showed positive trends.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PALATIN TECHNOLOGIES INC reported first quarter of fiscal year 2024 ended September 30, 2023 results: revenue $4.6 million in gross product revenue; $2.1 million in net product revenue.

Period: first quarter of fiscal year 2024 ended September 30, 2023
Revenue: $4.6 million in gross product revenue; $2.1 million in net product revenue
Result: preliminary results

Exact text from the filing

Preliminary Quarter Ended September 30, 2023 Vyleesi ® Product Revenue Results · 7 Consecutive Quarters of Double-Digit Growth in Product Revenue and Prescriptions Dispensed · $4.6 million in Gross Product Revenue o 11% growth over prior quarter; 100% growth over comparable quarter last year · $2.1 million in Net Product Revenue o 18% growth over prior quarter;

View on SEC.gov

Browse all earnings releases →

PALATIN TECHNOLOGIES INC filing history →

Source: SEC EDGAR

accession 0001654954-23-013131

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.